Aura Biosciences's AU-011 drug receives FDA orphan drug status for uveal melanoma
Biotech firm Aura Biosciences has received orphan drug designation from the US Food and Drug Administration (FDA) for its drug, AU-011, to treat patients with uveal melanoma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Eye Cancers | Food and Drug Administration (FDA) | Melanoma | Pharmaceuticals | Skin Cancer | Uveal Melanoma